Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report

Duo,Li  Jin; Rong,Jiang; Bin,Wang; Hua,Ma  Chun; Wei,Sun  Li; Yuan,Lv

doi:10.3892/ol.2015.3174

Transient partial response of poorly-differentiated thyroid carcinoma to sunitinib treatment: A case report

Authors:
- Li Jin Duo
- Jiang Rong
- Wang Bin
- Ma Chun Hua
- Sun Li Wei
- Lv Yuan
View Affiliations

Affiliations: Department of Tumor Intervention, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China
Published online on: May 4, 2015 https://doi.org/10.3892/ol.2015.3174
Pages: 492-496

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thyroid cancer is the most common endocrine malignancy, with an increasing prevalence worldwide. Poorly‑differentiated thyroid cancer (PDTC) is relatively rare and its prognosis is poor. To date, no ideal treatment strategy is available for patients with advanced recurrent PDTC, particularly for patients in crisis. However, partial success in treating thyroid cancer has been achieved with targeted therapy, and advances made in understanding the molecular biology of the tumor. The current study describes the case of a patient diagnosed with PDTC following presentation with hoarseness, orthopnea, and a large right neck mass. A transient partial response to sunitinib malate treatment was achieved for >3 months. In addition, the current study reviewed the relevant literature and discussed the therapeutic value of sunitinib as a more favorable treatment strategy for patients with advanced recurrent PDTC compared with the currently available treatments. Successful treatment with sunitinib, as well as molecular analysis of the tumor, occurred in the present case. Sunitinib was determined to have potential in treating thyroid tumors, however, larger prospective studies are required to validate the findings of the current case study prior to the application of this agent in clinical practice.

View Figures

View References

1	Agate L, Lorusso L and Elisei R: New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest. 35(Suppl): 3–9. 2012.PubMed/NCBI
2	National Cancer Institute, . Surveillance Epidemiology and End Results Program: SEER stat fact sheets: Thyroid cancer. http://seer.cancer.gov/statfacts/html/thyro.html#incidence-mortality15th– June. 2013
3	Cooper DS, Doherty GM, Haugen BR, et al: American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
4	Brose M, Nutting C, Jarzab B, et al: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol. 31(Suppl): Abstract 4. 2013.
5	DeSantis CE, Lin CC, Mariotto AB, et al: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
6	Dohán O, De la Vieja A, Paroder V, et al: The sodium/iodide symporter (NIS): characterization, regulation and medical significance. Endocr Rev. 24:48–77. 2003. View Article : Google Scholar : PubMed/NCBI
7	Schlumberger MJ: Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest. 22(Suppl): 3–7. 1999.PubMed/NCBI
8	Durante C, Haddy N, Baudin E, et al: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 91:2892–2899. 2006. View Article : Google Scholar : PubMed/NCBI
9	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
10	Perez CA, Santos ES, Arango BA, Raez LE and Cohen EE: Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 34:736–745. 2012. View Article : Google Scholar : PubMed/NCBI
11	Baudin E and Schlumberger M: New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 8:148–156. 2007. View Article : Google Scholar : PubMed/NCBI
12	Nixon IJ, Shaha AR and Tuttle MR: Targeted therapy in thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 21:130–134. 2013. View Article : Google Scholar : PubMed/NCBI
13	Antonelli A, Fallahi P, Ferrari SM, et al: New targeted therapies for thyroid cancer. Curr Genomics. 12:626–631. 2011. View Article : Google Scholar : PubMed/NCBI
14	Omur O and Baran Y: An update on molecular biology of thyroid cancers. Crit Rev Oncol Hematol. 90:233–252. 2014. View Article : Google Scholar : PubMed/NCBI
15	Barollo S, Bertazza L, Baldini E, et al: The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways. Invest New Drugs. 32:626–635. 2014. View Article : Google Scholar : PubMed/NCBI
16	Patel KN and Shaha AR: Poorly differentiated thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 22:121–126. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sherman SI: Targeted therapy of thyroid cancer. Biochem Pharmacol. 80:592–601. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kebebew E, Weng J, Bauer J, et al: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 246:466–470; discussion 470–461. 2007. View Article : Google Scholar : PubMed/NCBI
19	Nikiforova MN, Lynch RA, Biddinger PW, et al: RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 88:2318–2326. 2003. View Article : Google Scholar : PubMed/NCBI
20	Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF and de Micco C: Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 88:2745–2752. 2003. View Article : Google Scholar : PubMed/NCBI
21	Castellone MD and Santoro M: Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am. 37:363–374. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sherman SI: Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 37:511–524. 2008. View Article : Google Scholar : PubMed/NCBI
23	Cohen EE, Needles BM, Cullen KJ, et al: Phase 2 study of sunitinib in refractory thyroid cancer. In: ASCO Meeting Abstracts. 26. pp. 60252008;
24	Carr LL, Mankoff DA, Goulart BH, et al: Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 16:5260–5268. 2010. View Article : Google Scholar : PubMed/NCBI